Menu
Search
|

Menu

Close
X

Cerecor Inc CERC.OQ (NASDAQ Stock Exchange Capital Market)

4.91 USD
+0.02 (+0.41%)
As of Jun 22
chart
Previous Close 4.89
Open 4.89
Volume 34,738
3m Avg Volume 47,102
Today’s High 4.92
Today’s Low 4.87
52 Week High 5.72
52 Week Low 0.51
Shares Outstanding (mil) 31.41
Market Capitalization (mil) 154.24
Forward P/E 8.39
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
28
FY16
1
FY15
0
EPS (USD)
FY18
-0.124
FY17
0.517
FY16
-1.883
FY15
-1.216
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
8.39
34.14
Price to Sales (TTM)
vs sector
4.83
8.17
Price to Book (MRQ)
vs sector
6.27
4.30
Price to Cash Flow (TTM)
vs sector
11.35
22.70
Total Debt to Equity (MRQ)
vs sector
62.55
17.55
LT Debt to Equity (MRQ)
vs sector
59.35
13.12
Return on Investment (TTM)
vs sector
47.27
13.10
Return on Equity (TTM)
vs sector
100.57
15.09

EXECUTIVE LEADERSHIP

Uli Hacksell
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Peter Greenleaf
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Isaac Blech
Vice Chairman of the Board, Since 2012
Salary: --
Bonus: --
Mariam Morris
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Bernadine Fraser
Vice President, Clinical Operations and Project Management, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

400 E Pratt St Ste 606
BALTIMORE   MD   21202-3126

Phone: +1410.5228707

Cerecor, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions, including MDD, schizophrenia, Parkinson's disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT, which is the dominant form of COMT.

SPONSORED STORIES